iSpecimen Inc. Debt Securities, Available-for-sale, Amortized Cost
iSpecimen Inc. (ISPC) had Debt Securities, Available-for-sale, Amortized Cost of $466.45 thousand as of 2024-03-31, per its 10-Q filed 2024-05-07.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2025-04-14
- 2024-03-31: Debt Securities, Available-for-sale, Amortized Cost $466.45K.
- 2023-12-31: Debt Securities, Available-for-sale, Amortized Cost $2.66M.
- 2023-09-30: Debt Securities, Available-for-sale, Amortized Cost $2.94M.
- 2023-06-30: Debt Securities, Available-for-sale, Amortized Cost $6.21M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2024-03-31 | $466.45K 10-Q · filed 2024-05-07 |
| 2023-12-31 | $2.66M 10-K · filed 2025-04-14 |
| 2023-09-30 | $2.94M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $6.21M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $7.24M 10-Q · filed 2023-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |